Medulloblastoma, ChildhoodMOVENCT06898684
Medulloblastoma Online Video-based Exercise Pilot Study
A study testing Exercise in people with Medulloblastoma, Childhood, run by Aron Onerup at 2 sites in 2 countries.
Trial summary
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks. Read more about this study
- Who is it for?
- Ages 3 to 18 years
- Conditions the study is for
- Medulloblastoma, Childhood
- What is being tested?
- Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 9 Dec 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Inclusion Criteria: Completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry.
-
Exclusion Criteria: Inability to walk without support. Progressive disease.
-
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Germany1 site, 1 recruiting
- Not yet recruiting
Technical University Munich
München
Sabine Kesting, PhD, sabine.kusting@tum.de
Sweden1 site, 1 recruiting
- Recruiting
Queen Silvia C hildren´s Hospital
Gothenburg
Aron Onerup, MD, PhD, +46313421000, aron.onerup@gu.se
Aron Onerup
About this study
Official title: Medulloblastoma Online Video-based Exercise Pilot Study (MOVE)
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks.
Read the detailed description
Tumors of the central nervous system (CNS) represent 25-30% of all cases of pediatric cancer in Sweden. The survival for children with a brain tumor has improved over the last years. The 5-year overall survival rate is now 70%, resulting in a growing number or survivors every year. Malignant brain tumors typically have a poor prognosis, and curative treatment usually requires a combination of neurosurgery, chemotherapy and/or radiotherapy. For the survivors, the cure often comes at the cost of long-term side effects. Finding effective ways to mitigate the long-term side effects after childhood brain tumor is important, since they can severely impact the survivors´ daily life.
There is growing evidence that physical exercise is beneficial to cognition and improves cardiorespiratory fitness and motor function. It appears to be important that interventions start early, within 1-2 years after radiotherapy. For this to be feasible in international multicenter trials, the intervention and outcome assessments will need to be delivered remotely. Whether this is feasible in children treated for medulloblastoma is not known.
The investigators will perform a pilot study to provide pivotal information on whether exercise training can be remotely delivered in the home environment in children treated for medulloblastoma. This will take exercise training from an interesting research concept into a scalable intervention that can be offered regardless of geographic location of the patient. The study will further define the validity and feasibility of in-home outcome assessments of cardiorespiratory, muscular fitness and motor function in children treated for medulloblastoma. If shown feasible, this will work as a proof-of-concept and lead the way for including physical activity intervention in other childhood cancer treatment protocols as well. The results from this study will also enable the researchers to proceed in the planning of the first exercise intervention to be included upfront in an international childhood cancer treatment protocol, the upcoming Pan-European treatment protocol for standard-risk medulloblastoma in children (SIOP-MB6).
- Conditions
- Medulloblastoma, Childhood
- Being tested
- Exercise
- Keywords
- exercise, rehabilitation, medulloblastoma
- Medical subject headings
- Medulloblastoma, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseBehavioural
Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Experimental | Video-supervised exercise, offered three times per week for 12 weeks, followed by behavioral support towards incorporating physical activity into daily life for an additional 12 weeks. Receives: Behavioral: Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of the remote assessment and a digitally delivered exercise intervention
The researchers will test the feasibility of delivering the exercise intervention via video, defined as:
- Adherence to the intervention by number of completed intervention sessions Acceptable level: ≥70% adherence at 6 months.
- Data collection - feasibility of outcome measures Criteria: ≥ 90% of video-based measurements can be conducted according to protocol. ≥ 80% of PROM assessments can be completed as planned.
- Safety Documentation of adverse events (all occurring and documented adverse events associated with the intervention will be recorded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.).
- Acceptance and perceived usefulness Criterion: Qualitative analysis of interviews shows that the intervention is perceived as meaningful, feasible, and not too burdensome.
- Technical aspects Criterion: ≥ 90% of participants can complete video sessions without major technical problems, beginning after the first three sessions.
Measured: From enrollment to the end of exercise at 12 weeks and then for prolonged support for another 12 weeks.
Secondary outcomes (9)
Handgrip strength
Measured with a hand dynamometer
Measured: Change from baseline, until 3 and 12 months.
Physical activity
Activity counts per day, registered with accelerometry (Fibion Sens)
Measured: Change from baseline, until 1.5, 3, 6, and 12 months.
Patient-reported quality of life
Measured with Patient-Reported Outcomes Measurement Information System (PROMIS)-25.
Measured: Change from baseline, until 3 and 12 months.
Motor function
Assessed with the brief ataxia rating scale (BARS), higher numbers indicate worse outcomes.
Measured: Change from baseline, until 3 and 12 months.
Cardiorespiratory fitness
Assessed with the 3-min step in place test
Measured: Change from baseline, until 3 and 12 months.
Epigenetic age acceleration
Epigenetic age will be determined from DNA methylation analyses of DNA extracted from saliva samples.
Measured: Change from baseline, until 3 and 12 months.
Feasibility of the outcome measures
The researchers will develop the outcome assessments battery by removing outcome assessments that are not feasible through video.
Measured: 12 weeks
Cognitive function
Patient-Reported Outcomes Measurement Information System (PROMIS) cognitive function 7a.
Measured: Change from baseline to 12 weeks and 12 months.
Lower limb strength
We will assess lower limb strength with the five repetition sit-to-stand test, assessed with the number of seconds to perform the test. The same chair will be used across all time points.
Measured: Change from baseline until 3 and 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2025
- Study start9 Dec 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medulloblastoma, ChildhoodStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aron Onerup
- Sponsor type
- Other government
- Collaborators
- Göteborg University, Uppsala University, Region Västerbotten, Region Stockholm, Region Östergötland, Region Skane, Technical University of Munich, Universitätsklinikum Hamburg-Eppendorf
- Responsible party
- Sponsor-investigator, Aron Onerup, Vastra Gotaland Region
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06898684
- Sponsor's protocol ID
- MOVE pilot
- Acronym
- MOVE
- Status last verified
- Dec 2025
- First submitted
- 13 Mar 2025
- Last updated
- 16 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a small feasibility study and will not generate data that will be meaningful to share.
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Medulloblastoma Online Video-based Exercise Pilot Study (MOVE)
- ClinicalTrials.gov ID
- NCT06898684
- Acronym / sponsor ID
- MOVE / MOVE pilot
- Conditions
- Medulloblastoma, Childhood
- Keywords
- exercise, rehabilitation, medulloblastoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Aron OnerupOther government
- Collaborators
- Göteborg University, Uppsala University, Region Västerbotten, Region Stockholm, Region Östergötland, Region Skane, Technical University of Munich, Universitätsklinikum Hamburg-Eppendorf
- Study start
- 9 Dec 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 27 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks.
Detailed description
Tumors of the central nervous system (CNS) represent 25-30% of all cases of pediatric cancer in Sweden. The survival for children with a brain tumor has improved over the last years. The 5-year overall survival rate is now 70%, resulting in a growing number or survivors every year. Malignant brain tumors typically have a poor prognosis, and curative treatment usually requires a combination of neurosurgery, chemotherapy and/or radiotherapy. For the survivors, the cure often comes at the cost of long-term side effects. Finding effective ways to mitigate the long-term side effects after childhood brain tumor is important, since they can severely impact the survivors´ daily life.
There is growing evidence that physical exercise is beneficial to cognition and improves cardiorespiratory fitness and motor function. It appears to be important that interventions start early, within 1-2 years after radiotherapy. For this to be feasible in international multicenter trials, the intervention and outcome assessments will need to be delivered remotely. Whether this is feasible in children treated for medulloblastoma is not known.
The investigators will perform a pilot study to provide pivotal information on whether exercise training can be remotely delivered in the home environment in children treated for medulloblastoma. This will take exercise training from an interesting research concept into a scalable intervention that can be offered regardless of geographic location of the patient. The study will further define the validity and feasibility of in-home outcome assessments of cardiorespiratory, muscular fitness and motor function in children treated for medulloblastoma. If shown feasible, this will work as a proof-of-concept and lead the way for including physical activity intervention in other childhood cancer treatment protocols as well. The results from this study will also enable the researchers to proceed in the planning of the first exercise intervention to be included upfront in an international childhood cancer treatment protocol, the upcoming Pan-European treatment protocol for standard-risk medulloblastoma in children (SIOP-MB6).
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Exercise | Experimental | Behavioral: ExerciseVideo-supervised exercise, offered three times per week for 12 weeks, followed by behavioral support towards incorporating physical activity into daily life for an additional 12 weeks. |
Who may qualify
- Ages
- 3 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseModerate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance. | Behavioural | Exercise |
Primary outcome
Feasibility of the remote assessment and a digitally delivered exercise intervention
Time frame: From enrollment to the end of exercise at 12 weeks and then for prolonged support for another 12 weeks.
The researchers will test the feasibility of delivering the exercise intervention via video, defined as: 1. Adherence to the intervention by number of completed intervention sessions Acceptable level: ≥70% adherence at 6 months. 2. Data collection - feasibility of outcome measures Criteria: ≥ 90% of video-based measurements can be conducted according to protocol. ≥ 80% of PROM assessments can be completed as planned. 3. Safety Documentation of adverse events (all occurring and documented adverse events associated with the intervention will be recorded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.). 4. Acceptance and perceived usefulness Criterion: Qualitative analysis of interviews shows that the intervention is perceived as meaningful, feasible, and not too burdensome. 5. Technical aspects Criterion: ≥ 90% of participants can complete video sessions without major technical problems, beginning after the first three sessions.
9 secondary outcomes
Handgrip strength
Time frame: Change from baseline, until 3 and 12 months.
Physical activity
Time frame: Change from baseline, until 1.5, 3, 6, and 12 months.
Patient-reported quality of life
Time frame: Change from baseline, until 3 and 12 months.
Motor function
Time frame: Change from baseline, until 3 and 12 months.
Cardiorespiratory fitness
Time frame: Change from baseline, until 3 and 12 months.
Epigenetic age acceleration
Time frame: Change from baseline, until 3 and 12 months.
Feasibility of the outcome measures
Time frame: 12 weeks
Cognitive function
Time frame: Change from baseline to 12 weeks and 12 months.
Lower limb strength
Time frame: Change from baseline until 3 and 12 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2025.
- Individual participant dataSharing planned: No. This is a small feasibility study and will not generate data that will be meaningful to share.
Related trials for Medulloblastoma, Childhood
Active, not recruitingPhase 2
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Active, not recruitingPhase 2
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Brain and Central Nervous System Tumors
RecruitingPhase 1
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS
RecruitingPhase 1
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Medulloblastoma, Central Nervous System Embryonal Tumor
Not yet recruitingPhase 2
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Medulloblastoma, Childhood, run by Aron Onerup at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aron Onerup, MD, PhD (+46766185619, aron.onerup@gu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of the remote assessment and a digitally delivered exercise intervention (time frame: From enrollment to the end of exercise at 12 weeks and then for prolonged support for another 12 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.